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Abstract  
In the spontaneously hypertensive (SH) rat, hyperoxic inactivation of the carotid body 
produces a rapid and pronounced fall in both arterial pressure and renal sympathetic nerve 
activity (RSA). Here we show that carotid body de-afferentation through carotid sinus nerve 
denervation (CSD) reduces the overactive sympathetic activity (SA) in (SH) rats, providing 
an effective anti-hypertensive treatment. We demonstrate that CSD lowers renal (R) SA 
chronically and that this is accompanied by a depressor response in SH but not 
normotensive rats. The drop in blood pressure is not dependent on renal nerve integrity, but 
mechanistically accompanied by a resetting of the RSA-baroreflex function curve, 
sensitisation of the cardiac baroreflex, changes in renal excretory function and reduced T-
lymphocyte infiltration. We further show that, combined with renal denervation, CSD remains 
effective, producing a summative response indicative of an independent mechanism. Our 
findings indicate that carotid body de-afferentation is an effective means for robust and 
sustained sympathoinhibition, which is ripe for translating to patients with neurogenic 
hypertension. 
 
Introduction 
The causes of human essential hypertension remain unknown. It is established that in many 
patients, sympathetic nerve activity increases proportionately as hypertension develops and 
this may be a causative factor1-5, but it is unclear what triggers heightened sympathetic traffic 
(reviewed in6). Despite good pharmacological control of arterial pressure in most patients 
with essential hypertension, a significant proportion remain drug resistant or intolerant to 
medication7,8 and this has been highlighted as a growing problem9,10. This presents a 
significant clinical challenge, and provides the motivation to discover novel ways to control 
arterial pressure.  
 
Recently, the role of the carotid body (CB) chemoreceptors in the pathophysiology of 
cardiovascular disease is gaining considerable interest11-15. The sympathoexcitation in both 
sleep apnoea and heart failure may originate from enhanced activity of the CB 
chemoreceptors16-20. In both human patients and animal models of hypertension the CB 
chemoreflex-evoked sympathoexcitatory responses are enhanced15,21-23. However, the 
hypothesis that CB chemoreceptor drive plays an important role in the pathogenesis and/or 
maintenance of high arterial pressure was undetermined until most recently. We found that 
in spontaneously hypertensive (SH) rats, carotid sinus denervation (CSD) lowered arterial 
pressure by ~17 mmHg and that this was well maintained and tolerated11. These data are 
comparable to those in human hypertensive patients where inactivation of the CB with 100% 
oxygen reduced both arterial pressure and sympathetic activity24 supporting a causal role for 
peripheral chemoreceptors in the aetiology of neurogenic hypertension. Based on these 
data, and that CB resection has been performed and well tolerated for the treatment of 
dyspnoea in ~5,600 patients with asthma and chronic obstructive pulmonary disease 
(reviewed in14), we recently proposed that CB ablation may be an effective interventional 
strategy to control blood pressure in drug resistant hypertensive patients11,14.  
 
To assess the mechanisms underlying the hypotensive effect of CSD, we have made direct 
long-term simultaneous recordings of blood pressure and renal sympathetic activity (RSA) 
before and after CSD in conscious SH and Wistar rats. Given the current clinical interest and 
application of renal denervation (RD) in the treatment of drug resistant hypertension25-29, we 
have characterised the interaction between CSD and RD in combination to establish the type 
of interaction: summative, occlusive or facilitatory. Given that T lymphocytes have been 
shown to contribute to both angiotensin II and neurally mediated chronic hypertension30,31 we 
have assessed immune function following CSD.  Unlike Wistar rats, we find that the CB of 
the SH rat has resting tone driving hypertension, which is not dependent on renal nerves, 
depresses both the cardiac and sympathetic vasomotor baroreflex, and attenuates the 
adaptive immune response.  
 
 
 
  
Results 
All numerical data is reported as mean±standard error margin (SEM), with statistical 
significance (P<0.05) determined using two-way ANOVA (repeated measures for within-
subject comparison), followed where appropriate with the Holm-Sidek post hoc test.  
Transient inactivation of CB activity with hyperoxia 
In SH rats, exposure to 100% oxygen to inactivate the CB produced falls in both SBP (-12±4 
mmHg, n=5, P=0.047) and RSA (-2.9±0.4 μV, n=5, P=0.019) but no consistent change in 
heart rate (Fig 1). In stark contrast, pure oxygen was without significant effect on these 
variables when delivered to Wistar rats or SH rats after CSD (Supplementary Fig S1). These 
data provide evidence that in SH rats, tonic afferent activity emanating from the CB provides 
a potent drive for neurogenically mediated hypertension. 
 
Peripheral chemoreflex sensitivity in Wistar and SH rats 
Whilst previous studies have found increased reflex peripheral chemosensitivity in 
anaesthetised and decerebrate SH versus Wistar rats15, there are no data in conscious 
animals. Compared to Wistar rats, SH rats showed a more profound peripheral 
chemoreceptor reflex evoked bradycardia (-194±5 vs. -126±54 bpm, n=6, P=0.046) and RSA 
excitatory responses (13.4±0.8 vs. 9±0.6 µV, n=6, P=0.021), but not a pressor response 
(54±8 vs. 48±21 mmHg; p=0.811) following an i.v. sodium cyanide bolus.  
 
Time profile of RSA response to CSD in SH and Wistar rats 
Following the surgery related increase in RSA, there was a prompt and profound reduction in 
RSA below pre-operative baseline after CSD in SH rats (-1.94±0.3 µV, -56±12%; n=6, 
P=0.027; Fig 2a,b & c). The peak fall occurred 5 days post-CSD, and showed no signs of 
recovery throughout the 3 week experimental period. The fall in RSA was correlated 
temporally with a fall in MAP of -17±3 mmHg from a baseline of 137±7 mmHg (n=6, 
P=0.009). Spectral analysis also revealed a reduction in LF SBP from 3.5±0.2 to 2.5±0.2 
mmHg2 (P<0.012; Table 1) suggesting a global reduction in sympathetic traffic. In these 
animals, we also tested efficacy of CSD: Fig 2d shows that the sympathoexcitatory reflex 
response following i.v. sodium cyanide was blunted severely. Despite the substantial fall in 
basal RSA after CSD, a stressful stimulus (high frequency noise) continued to evoke a 
significant (P=0.013) sympatho-excitatory response in SH rats, the magnitude of which was 
not different to those evoked prior to CSD (before: 139±28%, after: 153±13%, n=6, P=0.529; 
Fig 4e). This test served to both validate the viability of our chronic recordings and showed 
that despite lower resting levels of RSA, alerting/arousal responses remained intact ensuring 
that fundamental visceral reactions were preserved. In Wistar rats, although there was no 
significant change in MAP after CSD (-6±5 mmHg, n=6), there was a small fall in RSA (-
0.9±0.1 µV, -18±7%, n=6, P=0.045; Fig 2a,b,c), which was much less than that seen in SH 
rats (P<0.01; Fig 2a,b,c).  
 
Baroreflex function improvement following CSD 
Cardiac baroreceptor reflex function curves were constructed recently after CSD11 and 
showed an increase in sensitivity, which might contribute to the hypotensive effect of CSD; 
hence, we have analysed this in more detail. Consistent with this was the new finding that 
spontaneous cardiac baroreflex gain increased from -1.16±0.09 to -1.53±0.27 bpm.mmHg-1 
after CSD (n=7, P<0.01. We also found an improvement in the sympathetic baroreflex 
sensitivity after CSD in SH rats (Fig 3) where the curve was shifted leftwards (n=5, P=0.032) 
and the operating point moved to the left and downward (P=0.026; Fig 3). An increase in the 
sensitivity of the curve was revealed by increases in both the upper and lower curvature 
parameters (see Supplementary Table S1) which translated into an increase in maximum 
gain (-6.8±1.7 to -9.7±1.9%.mmHg-1, P=0.028) towards that seen in Wistar rats 
(13.4±3.1%.mmHg-1). No significant changes in cardiac or sympathetic baroreflex function 
were found in Wistar rats post CSD (Supplementary Fig S2).  
Reduced T cell infiltration into the aorta after CSD and RD 
Inflammation, in particular the adaptive immune response, has been shown to play a 
significant role in the pathogenesis of hypertension30-32. We therefore examined the effects 
of CSD and RD on the percentage of total aortic leukocytes (CD45+ average total cells 
1.9x104 / aorta) and T lymphocytes (CD3+ average total cells 2.5x103 / aorta). The brainstem 
has also been identified as a site of increased inflammatory molecules during 
hypertension33,34, so we have examined the percentage of CD45+ CD3+ cells (average total 
cells 3.6 x102 / brainstem) within this tissue. As shown in figure 3b, compared to the surgical 
shams there were no significant differences in the percentage of aortic CD45+ cells following 
CSD or RD procedures. However, when we examined the number of aortic infiltrates of 
CD3+ cells, there was a significant decrease in both the CSD (Figure 3c-d; p<0.01) and RD 
groups (Figure 3c-d; p<0.01). Similarly, in single cell suspensions of whole brainstem 
homegenates, a significant reduction in percentage of CD3+ cells was determined following 
RD (Supplementary Figure S3; p<0.05) and a trend, that did not reach statistical 
significance, for a reduction in CD3+ cells in the CSD group. These data suggest that both 
CSD and RD procedures can reduce T cell mediated infiltration of tissue that has been 
associated with many forms of hypertension. 
Renal Excretory Function after CSD 
Given the alterations in arterial pressure and RSA, we looked to see if renal function was 
altered. Despite our observed reduction in arterial pressure, SH rats showed an increase in 
24-hour urine volume at 12 days following CSD (from 4.25±0.28 to 5.57±0.32 ml/24h/100g 
body weight; p<0.05), which was sustained at days 21 and 28. This was accompanied by an 
increase in creatinine clearance (0.94±0.03 to 1.15±0.07 ml/min; p<0.01), indicating an 
increase in glomerular filtration rate (GFR). The total protein in urine decreased significantly 
(10.5±1.0 to 8.7±0.8 mg/ml; p<0.05), albuminuria was lower after CSD but not significant 
(0.57±0.05 to 0.45±0.05 mg/ml; p=0.067), although water intake also increased significantly 
(10±1.2 to 12.8±1.6 ml/24h/100g body weight; P<0.01). For comparison, Wistar rats had a 
lower total protein and albumin level in their urine compare to SH rats before denervation: 
9.75±0.84 vs 10.49±0.77 mg/ml and 0.40±0.06 vs 0.57±0.05 mg/ml, respectively. The water 
intake and creatinine clearance was similar between Wistar and SH rats before denervation: 
30.81±2.13 versus 30.49±2.13 ml/24h and 0.83±0.07 versus 0.94±0.03 ml/min, respectively.  
Taken together these data indicate that the progression of glomerular kidney 
damage/leakage in SH rats may have been retarded by CSD. 
 
Time to sympatho-inhibition after CSD in SH rats 
In conscious SH rats it was not possible to assess the precise time to onset of the depressor 
and sympatho-inhibition following CSD, due to the side effects of surgery and anaesthesia. 
To this end, we recorded internal cervical and lumbar sympathetic post-ganglionic nerves 
simultaneously before and after CSD in in situ unanesthetised decerebrated SH rats. Figure 
4 shows that by 40 min there was already a significant decrease in sympathetic nerve 
activity in all outflows and that this was due, in part, to a decrease in the amplitude of 
respiratory-modulated discharge (P<0.05; Fig 4b). The peak response was achieved at 60 
min post CSD as activity levels at 75 or 90 min were not different to the level recorded at 40 
min post CSD but were different to their own baseline (both P<0.01; Fig 4c). Consistent with 
the reduction of respiratory-sympathetic modulation, we found a decrease in HF SBP in 
conscious SH rats after CSD (from 4.52±0.3 to 3.9±0.3 mmHg2; n=7, P<0.05). 
 
Comparing uni- versus bilateral CSD in SH rats  
We wished to test any difference in the sympathoexcitatory drive from the left versus the 
right CB as well as their individual responses. Figure 5 shows the time profile of the 
response in SBP following unilateral and subsequent bilateral CSD. Unilateral CSD, whether 
targeting the left (n= 4) or right side (n= 4) produced no change in SBP (Supplementary 
Table S2). The fall in SBP achieved when bilateral CSD was staggered in time by 15 days 
(i.e. denervating left then right CB, or denervating right then left CB) was no different to the 
response when both the CBs were denervated at the same time (-16±2 vs. -17±3 mmHg, 
respectively, p=0.831). In our in situ preparation which allowed high temporal resolution of 
changes in sympathetic activity (see above), unilateral CSD did not produce a measureable 
change in any of the recorded variables.  
 
Systolic blood pressure response to combined CSD and RD  
Given the current interest in RD25-29, the relative potency and interaction (occlusive, 
summative, facilitatory) of RD versus CSD and was deemed scientifically and clinically 
important. All sham-operated SH rats showed a time related increase in SBP (4±4 and 3±2 
mmHg for sham CSD-RD and sham RD-CSD respectively; Figs 6 & 7). The efficacy of RD 
was confirmed by measuring renal noradrenaline content after RD (with or without 
concurrent CSD), which showed a significant reduction compared to sham controls (RD 
alone: 45±6; RD with CSD: 31±9; sham: 443±54 pg/100µg protein; n=18, P<0.01). The data 
reported herein are all expressed relative to the pre-operative control level.  
 
Figure 6 shows the time profile of the SBP response to RD followed by CSD (Fig 6a) and 
CSD followed by RD (Fig 6b). In SH rats, performing RD first produced a fall of SBP of -9±2 
mmHg from a baseline of 166±5 mmHg (n=6, P<0.013). A further fall of -12±3 mmHg 
ensued after subsequent CSD (P<0.001) and showed no recovery over the observational 
period. In SH rats undergoing the CSD-RD surgical sequence, basal SBP was 160±8 
mmHg, CSD alone evoked a prompt fall of -14±2 mmHg (n=7, P<0.001) with a further fall of 
-6±2 mmHg (P<0.001) after RD; no recovery was observed over the time course of the 
study. The total fall (-17±2 mmHg) was not different to that measured with the reversed 
sequence of RD-CSD (-20±3 mmHg; p=0.363). These data are summarised in Figure 7 and 
show an additive interaction between RD and CSD that this is similar irrespective of the 
order in which the surgical procedures are carried out in SH rats. CSD, but not RD, produced 
significant bradycardia (P=0.018) and a small reduction in respiratory frequency (P<0.01) in 
SH rats (Table 1). Table 1 documents spectral frequency analysis of both pulse interval and 
SBP after RD-CSD and CSD-RD. RD alone resulted in an increase in spontaneous 
baroreflex gain (-1.73±0.4 bpm.mmHg-1 mmHg; p<0.01; Table 1) and decrease in CD3+ 
cells (Figure 3b-d; p<0.01). Figure 6c demonstrates that the reflex bradycardia and pressor 
responses to sodium cyanide (i.v.), used to activated peripheral chemoreceptors in 
conscious SH rats, were abolished after bilateral CSD. 
 
Discussion  
Our data demonstrate that the CB in the conscious SH rat is constitutively active and 
provides a tonic pro-hypertensive drive. Mechanistically, the anti-hypertensive effects of 
CSD in SH rats include: a substantial reduction in sympathetic nerve discharge including that 
to the kidney involving a reduction of respiratory modulation; a resetting of the sympathetic-
baroreflex over lower arterial pressures; an improvement in spontaneous cardiac-baroreflex 
gain; possible changes in renal excretory function; and a reduction in vascular T cell 
infiltration.  Unilateral CSD, whether left or right side, was ineffective in reducing arterial 
pressure, but subsequent resection of the contralateral side remained an effective anti-
hypertensive therapy. In conscious SH rats, we show that CSD is more potent as an anti-
hypertensive intervention than RD, but that the renal nerves are not necessary for the 
hypotensive effect of CSD. Combining RD with CSD, or reversing the sequence (CSD then 
RD), gives an additive response that is similar in magnitude irrespective of the order in which 
the surgical procedures are performed. 
 
RD in young SH rats prevents the full development of hypertension35,36. The fall in arterial 
pressure of ~9 mmHg we report herein following RD in Wistar rats is consistent with 
previous studies in Sprague Dawley rats37 but not with Wistar Kyoto rats where arterial 
pressure was unaltered35,38.  Previous reports in SH rats demonstrated larger falls in arterial 
pressure after RD (~19 mmHg36,38) relative to our results (~9 mmHg). The difference may 
reflect the use of tail cuff/indwelling catheters rather than radio-telemetry, and between-
group versus within-animal analyses. Despite these quantitative differences, renal nerves 
(afferent and/or efferent) play a tonic role in regulating arterial pressure in some strains of 
normotensive and SH rats, as reviewed recently39.  
 In conscious SH rats, our finding that the CB chemoreflex sensitivity is elevated relative to 
the Wistar animal is consistent with prior data from animals and humans15,21-23. For the first 
time, we describe heightened CB tonicity in SH rats as revealed by a depressor and 
sympatho-inhibitory response to hyperoxia in SH but not Wistar rats. This suggests that the 
CB has elevated activity in the SH rat providing excitatory drive to the generation of 
sympathetic vasomotor tone that in turn contributes to the hypertension, as recently 
described in hypertensive human patients24. It may also explain why CSD is effective in 
producing a long-term anti-hypertensive response. The tonic activity in SH rats may result 
from increased expression of ASIC3 and TASK1 - two acid-sensing non-voltage gated 
channels15. Others suggest that the balance between carbon monoxide and hydrogen 
sulphide within the CB and the activity of HIF-1α versus HIF- α play a role40. Animal 
models of chronic heart failure have revealed that CB chemoreceptor activity is augmented 
by: angiotensin II receptors41, impaired nitric oxide synthase activity20, reduced CB blood 
flow42, enhanced adenosine monophosphate-activated protein kinase43 and 
inflammation44,45. Heightened sympathetic drive to the arterioles of the CB itself may also 
contribute to its hyperactivity due to hypoperfusion (via vasoconstriction and vascular 
remodelling46) and inflammation. 
 
Because of the complications of anaesthesia and surgical recovery, we were unable to 
determine the precise time-dependent effects following CSD in conscious SH rats. Using our 
in situ rat preparation, a fall in perfusion pressure and sympathetic activity occurred at 40 
min post CSD indicating a relatively rapid response. Presumably 40 min permits a 
reconfiguration of the cardio-respiratory brainstem network in the in situ rat, as reflected by a 
reduction in both respiratory-sympathetic coupling and the magnitude of the Traube-Hering 
wave amplitude. Consistent with reduced respiratory-sympathetic coupling, we saw a 
decrease in HF SBP spectra in conscious SH rats after CSD. Given that respiratory-
sympathetic coupling contributes significantly to vascular resistance and arterial pressure 
development the SH rat47, this could be a major mechanism for the CSD evoked anti-
hypertensive effect.  
 
It was evident that removal of a single CB, whether the left or right, in vivo or in situ, was 
ineffective in lowering arterial pressure in SH rats, although there was a brief reduction in 
respiratory frequency perhaps indicative of a transient effect. Given that CB afferents 
terminate in the commissural NTS with axons traversing the midline providing ample 
innervation of contralateral targets48, it perhaps is not surprising that unilateral CSD was not 
effective long-term.  
 
On subsequent removal of the second CB from a SH rat with chronic, unilateral CSD, arterial 
pressure fell precipitously; the level reached was not different to that recorded following a 
procedure where both CBs were removed at the same time. This suggests that any 
compensation occurring after loss of a single CB does not affect the efficacy of response 
following contralateral CB denervation. Whether these findings relate to humans with 
hypertension is unknown, but provides the following predictions: (i) unilateral CSD may be 
effective transiently in lowering arterial pressure and compensated for with time; (ii) 
subsequent CB resection following a unilateral procedure will cause a potent hypotensive 
effect. For safety reasons, a clinical study should start with unilateral CB ablation; thus, 
knowing that a hypotensive effect persists following staggered bilateral CSD (i.e. not 
ameliorated by a prior unilateral intervention) is important pre-clinical information. 
 
Previously, we have shown that CSD in young, pre-hypertensive SH rats prevented the full 
manifestation of hypertension, and lowered arterial pressure in adult SH rats11. Using both 
power spectral analysis and hexamethonium to block ganglionic transmission, we provided 
indirect evidence that the hypotension was caused, in part, by a generalised reduction in 
sympathetic activity11. Here, we demonstrate for the first time that the CSD induced 
hypotension was accompanied with a substantial reduction in RSA that fell with a similar 
time course. Despite this robust reduction of ~55% in RSA, we showed that animals were 
not left sympathetically incompetent and, importantly, could respond vigorously to a stressor 
stimulus. Given that lumbar and cervical sympathetic outflows also fell (as shown acutely), 
we suspect that there is widespread sympathoinhibition following CSD and that it is not 
confined to the kidneys. This is supported by a chronic reduction in low frequency spectra of 
SBP. This has important clinical implications regarding the applicability of CSD beyond 
hypertension, to conditions such as heart failure, sleep apnoea and insulin resistance where 
there is excessive and pathological sympathetic activity14.  
 
The mechanisms for blood pressure reduction following CSD are likely to be numerous, and 
operate over different time scales giving a persistent effect. Our hyperoxia data clearly 
shows that removal of CB tone in SH rats can, at least acutely, provide sympathoinhibition. 
This may suggests a hypoxic drive within the CB of the SH rat, which might be the stimulus 
for the increased density of small vessels in the CB of SH versus normotensive rats46. 
However, we do not rule out non-hypoxic intra-CB drives to explain the tonicity within the SH 
rat CB. Other mechanisms by which CSD lowers blood pressure include an improvement in 
both cardiac and sympathetic vasomotor limbs of the baroreflex after CSD (see11). Because 
our method of CSD removes innervation of the carotid sinus baroreceptors, the improvement 
in baroreceptor reflex function must be of aortic baroreceptor origin. Based on this 
observation, it is expected that selective removal of the carotid body, sparing carotid sinus 
baroreceptors, would be predicted to enhance their gain also and produce a greater anti-
hypertensive effect. The known antagonistic interaction between chemo- and baro- afferents 
both centrally (at a neuronal level within nucleus tractus solitarii49) and of their respective 
reflex responses50 could explain this beneficial result as enhanced baroreflex function can 
contribute to the long-term lowering of blood pressure and sympathetic activity in dogs51 and 
humans52. We do not rule out improved compliance of the aorta, central plasticity and/or 
improved cardiac vagal transmission to explain better baroreflex function after CSD in SH 
rats. The finding of reduced internal cervical sympathetic activity may improve brainstem 
blood flow; given that the SH rat brainstem is hypoperfused, improving flow may contribute 
to reducing arterial pressure53. Our observation of increased urine production and GFR in 
the face of decreased systemic arterial pressure, indicates that CSD may be associated with 
active improvements in renal excretory function. This may be mediated at least in part 
directly through the substantial inhibition of renal sympathetic activity, and may contribute to 
the hypotensive effect of CSD through fluid excretion. The reduced percentage of vascular 
and brainstem infiltrates of T lymphocytes is unlikely to contribute to the prompt fall in arterial 
pressure because of its rapid time course but may assist in the long term maintenance of the 
hypotensive effect of CSD especially since T lymphocytes have been shown to contribute to 
both angiotensin II and neurally mediated chronic hypertension54,55. We speculate that the 
sympathoinhibitory effect of CSD contributes to reduced T cell infiltration in the aorta and 
brainstem described herein, which could improve vascular compliance including aortic 
baroreceptor sensitivity, and improved baroreflex transmission centrally33,34. The location of 
the vascular immune cell infiltrates is unknown, but we speculate based on previous 
studies56 that these cells predominantly accumulate in the adventitia and perivascular 
adipose tissue of blood vessels. Given the sympathetic innervation of immune system 
organs such as the spleen, thymus and bone marrow26, we suggest that reductions in 
sympathetic activity may be the trigger for the anti-inflammatory response thereby breaking 
this positive (and pathological) feedback loop6. 
 
One successful new anti-hypertensive interventional approach is renal denervation (RD), 
which appears to be a safe treatment in some humans with drug-resistant hypertension25-29. 
In one study blood pressure was lowered by >10 mmHg with a high success rate (84%), 
although all patients remained hypertensive and their anti-hypertensive medication was 
maintained25. In contrast, an 84% success rate was not confirmed by other groups who 
reported no overall change in arterial pressure, although some individuals did respond27 or 
around a 40-50% blood pressure response rate26,28,29. Given these findings, and the recent 
success of unilateral CB resection in a heart failure patient57, CB ablation to control arterial 
pressure in drug resistant hypertensive patients could be considered. Thus, the following 
scenarios are imagined and include patients in which RD has: (i) not lowered arterial 
pressure to target; (ii) not circumvented prescribed and poorly tolerated medication; (iii) 
failed and (iv) not been possible due to renal artery stenosis or bifurcation. Thus, it becomes 
critical to study any interaction on arterial pressure following combined RD and CSD as well 
as CSD alone procedures. 
 
The finding that unilateral CB resection in a heart failure patient was effective in correcting 
partially both cardiac autonomic balance and cardiac baroreflex gain57 yet ineffective in 
altering these variables in SH rats is curious. Clearly, heart failure and hypertension have 
distinct pathologies, which could explain this difference. Equally, there may be differences in 
CB signalling mechanisms between SH rats and humans that could contribute to response 
differences between unilateral versus bilateral CB resection. This remains an open question. 
 
In conclusion, there is an additive anti-hypotensive interaction between CSD and RD, which 
is unaffected by either the order or timing of the procedures. Bilateral CSD provides a potent 
and persistent anti-hypertensive response in SH rats accompanied by substantial 
sympathoinhibition in multiple outflows, improved baroreflex and renal function, and reduced 
T lymphocyte infiltration in the aorta and brainstem. Whether CSD offers therapeutic benefit 
to drug resistant/intolerant human patients with sympathetically mediated diseases is 
currently undergoing clinical trial. 
 
Methods 
Animal experiments were conducted in accordance with the UK Animals (Scientific 
Procedures) Act 1986 and associated guidelines and approved by the University of Bristol 
Ethics Committee. Adult male (12 weeks; n=38) SHR and Wistar rats (12 weeks; n=6) bred 
in the University of Bristol Animal Services Unit were used. For all surgeries rats were 
anaesthetised with ketamine (60 mg kg−1; i.m.) and medetomidine (250 μg kg−1, i.m.) and 
aseptic techniques used.  
 
Renal and carotid body (CB) surgery 
For CSD, the CB was approached via an anterior midline neck incision and the carotid sinus 
nerve branches sectioned11.  Sham-operated rats underwent the same surgical procedures 
to expose the CB but the carotid sinus nerves were left intact. Unilateral CSD rats (SH, n=8) 
were randomised to have either their left (n=4) or right (n=4) carotid sinus denervated first, 
followed by contralateral denervation 14 days later. On denervating the second CB a 
transient apnoea occurred in all SH rats with some requiring resuscitation. This apnoea was 
not observed in Wistar rats. No post-surgical mortalities occurred suggesting that there were 
no lethal apnoeic episodes post-CSD, and all rats gained weight normally. To assess the 
efficacy of CSD, arterial pressure was recorded (and from this heart rate and respiratory 
frequency were derived) during an injection of sodium cyanide (NaCN, 100 µl 0.04% i.v.), 1-
2 weeks post-CSD. 
 
Bilateral renal denervation (RD) was achieved via a retroperitoneal incision to allow 
retraction of each kidney and exposure of the renal artery. The nerves and adventitia were 
stripped from the renal artery and renal plexus, which were then painted with a dilute (10% in 
ethanol) phenol solution. Sham-operated rats had both kidneys exposed via the 
retroperitoneal incision and the renal nerves visualised but left intact. 
 
Renal sympathetic activity response to CSD 
In rats (SHR n=6, Wistar n=6) following implantation of the blood pressure catheter into the 
abdominal aorta and closure of the midline incision33, the right kidney was exposed via a 
retroperitoneal incision. Using a fine round-tipped glass hook the renal nerve was freed from 
the surrounding connective tissue, and a small patch of parafilm slipped underneath to 
prevent fluid ingress. The nerve was passed over the electrodes from a sympathetic nerve 
activity telemeter (Model TR46SP, Telemetry Research Ltd, Auckland, New Zealand), 
carefully fixed in place using sutures, then isolated from surrounding tissue with silicone 
elastomer (Kwik-Sil, WPI Inc.). A polyurethane catheter (0.033 in (∼0.84 mm) OD; 0.014 in 
(∼0.36 mm) ID; Micro-Renathane, Braintree Scientific) was implanted into the left femoral 
vein, connected with  to a transcutaneous port between the scapulae and flushed every 2-3 
days with saline containing heparin (100 U ml−1) and penicillin G (2000 U ml−1) solution11. 
On days -2 and 8, the venous lines were connected and solutions of phenylephrine (0.1 
mg/ml) and sodium nitroprusside (0.1 mg/ml) were infused i.v. to obtain ramp increases in 
arterial pressure of 1-2 mmHg/s between ~60-180mmHg.  These data were then used to 
generate 5-parameter sigmoidal regression baroreflex function curves. A brief sodium 
cyanide bolus (NaCN, 100 µl 0.04% i.v.) was given to stimulate peripheral chemoreceptors. 
The ‘zero’ level of renal sympathetic activity (RSA) was assessed after ganglionic blockade 
using hexamethonium tartrate (100 µl, 10mg/ml i.v.). To assess any tonic activity generated 
by the CB, hyperoxia was used to ‘silence’ the CBs by briefly placing their cages into a 
plexiglass box connected to a 100% oxygen source on day -1. Arterial pressure was 
recorded 24 hours per day while RSA was recorded for 60 minutes at approximately the 
same time each day when animals were observed to be resting quietly.  
 
Arterial pressure and RSA signals were sampled at 500Hz using an analog-digital data 
acquisition card (PCI 6024E National Instruments, Austin, Texas) and continuously 
displayed by a data acquisition program (Universal Acquisition 11, University of Auckland, 
Auckland, New Zealand). Heart rate (HR) was derived from the arterial pressure waveform. 
The RSA signal was amplified, filtered between 50-5000 Hz, full-wave rectified and 
integrated using a low pass filter with a 20ms time constant. At least 7 days were allowed for 
recovery before a 3 day baseline period was recorded. Arterial pressure and heart rate were 
recorded for 24 hours a day. To avoid movement artefact, RSA was recorded for an hour at 
the same time each day while the rats undisturbed in their home cage were observed to be 
quiescent. On days -2 and 7, rats were exposed to a brief burst of high frequency noise, 
which produces a stress increase in RSA. The magnitude of this response was used to 
check that the RSA signal remained viable and responsive throughout the experiment. 
 
Renal Excretory Function 
Rats were housed in metabolic cages with free access to water and food for 24h. Blood was 
collected via withdrawn from tail vein. Plasma and urine creatinine were measured by 
improved Jaffe method with the commercially available QuantiCrom Creatinine Assay Kit 
(DICT-500, Universal Biologicals, Cambridge, UK)58. Creatinine clearance was estimated as 
(urinary creatinine [μmol/l] × volume urine produce in 24 hours [mls])/(plasma creatinine 
[μmol/l] × 1440 [minutes]). Urinary albumin was measured by the improved BCG method59 
with the commercially available Albumin Assay (Randox Laboratories Ltd, Crumlin, UK) and 
the total protein was measured by the Lowry method60 with the DC Protein Assay Kit (Bio-
Rad Laboratories Ltd, Hemel Hempstead, UK).  Urinary sodium was measured using an ion-
selective electrode (Cole-Parmer, London ,UK). Renal excretory function was assessed over 
a 24 h period before (Day -2) and after (Day 28) CSD (n=6) or sham (n=6) surgery. 
 
Renal noradrenaline content 
The left kidneys were crushed in liquid nitrogen and homogenised in an extraction buffer 
(0.01M HCl, 1mM EDTA, 4mM sodium matabisulfate). Samples were centrifuged (8000 rpm 
for 30 min) and the supernatant protein concentration determined by DC-Protein assay 
(BioRad, UK, No 500-0112). Tissue noradrenaline content was assessed by ELISA (Alpco 
Diagonscics, USA, No 17-NORHU-E01-RES) and normalised to protein concentration. 
 FACS analysis of cellular inflammation 
Analysis of T cells in vascular homogenates of the aorta and brainstem was performed using 
fluorescence-activated cell sorting (FACS).  To analyze leukocytes in the aorta and brain, 
tissue was digested using collagenase type IX (125u/ml); collagenase type IS (450U/ml) and 
hyaluronidase IS (60U/ml) dissolved in 20 mM HEPES-PBS buffer for 30 minutes at 37o C, 
while constantly agitated. The dissolved tissue was then passed through a 70 m sterile filter 
(Falcon, BD), yielding a single cell suspension. An additional step was applied for brain 
tissue using a 30% / 70% percoll gradient to separate out the mononuclear cell layer.  All 
cells were then washed twice with FACS buffer (0.5% bovine serum albumin in PBS) then 
counted, stained and analyzed using multi-color flow cytometry61.  Antibodies (BD 
Biosciences) used for staining were as follows: V450 anti-CD45; PE anti-CD3.  After 
immunostaining, cells were re-suspended in FACS buffer (0.5% bovine serum albumin in 
PBS) and analyzed immediately on a LSR-II flow cytometer with DIVA software (Becton 
Dickinson).  Data were analyzed with FlowJo software (Tree Star Inc., Ashland, Oregon, 
USA).  
 
In situ working heart-brainstem preparation 
As described originally62, animals were anaesthetized deeply (halothane), heparinised (1000 
units i.p.), bisected below the diaphragm and decerebrated pre-collicularly. Anaesthesia was 
terminated. Preparations were transferred to a recording chamber and a double lumen 
cannula was placed into the descending aorta for retrograde perfusion with a Ringer solution 
containing in mM: NaCl (125), NaHCO3 (24), KCl (3), CaCl2 (2.5), MgSO4 (1.25), KH2PO4 
(1.25), and D-glucose (10). Ficoll (MWt 20,000; 1.25%) was added as an oncotic agent and 
the perfusion solution was saturated with 95% O2-5% CO2 (pH 7.35-7.4; osmolality 290±5 
mosm±kg H2O−1 at 31°C). Perfusion pressure was maintained between 60-80 mmHg with 
additions of arginine vasopressin (200–400 pM, Sigma). A muscle relaxant, vecuronium 
bromide (4 µg/ml; Organon Teknica, Cambridge, UK) was added to the perfusate. 
Recordings from the phrenic, lumbar and internal cervical sympathetic nerves were made 
simultaneously using custom bipolar glass suction electrodes. Signals were amplified (x20k), 
filtered (60-3000 Hz), rectified and integrated (50 ms time constant) and the noise level 
(obtained at the end of the experiment) subtracted. Phrenic triggered averaging of integrated 
sympathetic activity (over 10 phrenic cycles) allowed peak-to-trough amplitudes of the 
respiratory related sympathetic burst to be measured. The Traube-Hering waves were also 
analyzed using phrenic triggered averaging. 
 
Cardiovascular responses to CSD and RD 
Radio-telemeters (PA-C40, Data Sciences Inc, St Paul, Minnesota, USA) were implanted as 
described before33,34. After seven full days of recovery, four days of baseline arterial 
pressure was recorded prior to the first surgical intervention (All SH rats: CSD, n=7; sham-
CSD n=7; RD, n=6; sham-RD n=6). 21 days after CSD/sham-CSD, RD surgery was 
performed; conversely, 14 days after RD/sham-RD, CSD surgery was performed. Arterial 
pressure was recorded for 5 min every hour, 24 hours per day using Hey Presto software, 
and heart rate and respiratory rate were derived from the arterial pressure waveform33. The 
data shown for cardiovascular parameters and ventilatory frequency represent daily 
averages from these 5 minute periods. On the final day of the experiment, rats were 
euthanized (sodium pentobarbital 40mg/kg i.p.) and the kidneys extracted, weighed and 
frozen in liquid nitrogen for a noradrenaline assay. The aorta was removed for fluorescence-
activated cell sorting (FACS) and analysis of cellular inflammation (see below). 
 
Power spectral analysis 
Power spectral density was computed using purpose-written software33. The following 
frequencies were calculated in normalized units: <0.27 Hz (very low frequency; VLF), 0.27-
0.75 Hz (low frequency; LF) and 0.75-3.3 Hz (high frequency; HF). The ratio of the LF to the 
HF component was used as an indicator of cardiac sympatho-parasympathetic balance. 
Spontaneous baroreflex gain was computed and respiratory rate was inferred from the 
peaks of respiratory modulation of the systolic pressure frequency spectrum.  
 
Data analysis 
From the arterial pressure waveform, values for systolic, diastolic, mean pulse pressure, 
heart rate and respiratory rate were derived. RSA is expressed as a percentage, where 
100% is the average integrated value across the baseline period. Values are presented as 
mean ± SEM except where stated. Data were compared between baseline and CSD, and 
where applicable, RD time points, by repeated measures two-way ANOVA, followed where 
appropriate by the Holm-Sidek post hoc multiple comparison test. Differences within or 
between groups with p values of <0.05 were considered significant. 
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CSD + RD (n=7) 
MBP 
(mmHg) 
HR  
(beats.min
-
1
) 
sBRG  
(ms.mmHg
-1
) 
RR  
(breaths.min
-
1
) LF:HF (PI) 
VLF  
(SBP - 
mmHg
2
) 
LF  
(SBP - mmHg
2
) LF:HF (SBP) 
Absolute 
Baseline 134±6 333±5 0.66±0.05 71±2 0.21±0.01 5.3±0.6 3.5±0.2 0.72±0.03 
CBD 120±6**# 314±6* 0.97±0.14**# 64±2**# 0.22±0.01 5.8±0.05 2.5±0.2* 0.60±0.06** 
RD 117±5*# 317±7 1.1±0.19*# 68±2 0.23±0.01 5.7±0.04 2.4±0.2 0.52±0.05* 
Change 
Diff CBD -14±3**# -19±7* 0.30±0.12**# -7±1**# 0.014±0.009 0.45±0.28 -0.99±0.16*# -0.13±0.04** 
Diff RD -4±3* 5±4 0.10±0.07* 5±2 0.012±0.008 -0.36±0.58 -0.04±0.14 -0.07±0.02 
  Total Fall -17±3 -16±5 0.44±0.09  -2±1 0.025±0.008 0.40±0.43 -0.52±0.24 -0.20±0.03 
Sham + RD (n=7)                 
Absolute 
BASELINE 132±8 326±4 0.87±0.18 76±5 0.20±-0.01 5.3±0.6 3.2±0.3 0.65±0.03 
Sham 135±5 306±7* 0.81±0.12 75±4 0.21±0.01 5.8±0.5 3.3±0.3 0.62±0.03 
RD 122±9* 300±2 0.821±0.08 69±4 0.23±0.02 5.7±0.4 2.6±0.2 0.57±0.03 
Change 
Diff Sham 3±3 -19±7* -0.06±0.16 0±1 0.01±0.01 0.48±0.28 0.11±0.18 -0.03±0.01 
Diff RD -8±7* -6±10 -0.082±0.09 -6±4 0.01±0.02 -0.36±0.58 -0.63±0.30 -0.04±0.02 
RD + CSD (n=6)                 
Absolute 
BASELINE 143±5 325±3 0.67±0.04 86±4 0.21±0.01 5.9±0.3 3.4±0.2 0.58±0.01 
RD 137±5*# 324±7 0.72±0.04 88±4 0.21±0.01 5.6±0.1 3.2±0.2 0.56±0.01 
CBD 126±4* 313±5* 0.78±0.04 76±2** 0.21±0.01 5.6±0.3 2.9±0.1* 0.50±0.02** 
Change 
Diff RD -6±2*# -1±3 0.06±0.03 2±1 0.005±0.012 -0.35±0.14 -0.15±0.13 -0.02±0.01 
Diff CBD -11±3* -11±5* 0.06±0.03 -11±2** 0.001±0.007 0.03±0.21 -0.35±0.02* -0.07±0.01** 
  Total Fall -17±2 -12±4 0.12±0.03 -9±2 0.005±0.011 -0.33±0.17 -0.50±0.08 -0.09±0.01 
Sham + CSD (n=6)                 
Absolute 
BASELINE 128±8 329±9 0.74±0.07 74±4 0.19±0.01 5.9±0.3 3.5±0.2 0.65±0.03 
Sham 132±9 323±5 0.69±0.06 77±5 0.20±0.01 5.5±0.3 3.1±0.2 0.65±0.02 
CBD 122±9* 313±9* 0.85±0.06 65±2** 0.20±0.01 5.7±0.3 2.9±0.15 0.59±0.03* 
Change 
Diff Sham 4±2 -6±5 -0.05±0.02 3±1 0.004±0.007 -0.39±0.32 -0.35±0.27 0.01±0.01 
Diff CBD -11±6* -10±5* 0.16±0.04 -10±3** -0.005±0.005 0.23±0.24 -0.20±0.17 -0.06±0.03* 
 
Table 1 
Mean arterial pressure (MAP), heart rate (HR), spontaneous baroreceptor reflex gain (sBRG), respiratory rate (RR) and spectral analyses of 
pulse interval (PI) and systolic blood pressure (SBP; HF, high frequency; LF, low frequency; VLF, very low frequency) after carotid sinus nerve 
denervation (CSD) and renal denervation (RD) and combinations of these interventions. Sham operated data are given for each procedure.    
 
 
Figure 1 
The carotid bodies in hypertensive rats 
are tonically active. 
Comparing the effect of 100% oxygen to 
depress tonic carotid body (CB) activity in 
Wistar (n=6) and SH (n=6) rats on SBP 
(a) and RSA (b, c). The CB in SH rats, 
but not Wistar rats, exhibits tonic activity 
that is functionally relevant and 
contributes to basal arterial pressure (d) 
and sympathetic activity (e). Data shown 
as mean±sem *p<0.05, repeated 
measures ANOVA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
Carotid sinus denervation causes substantial renal 
sympathoinhibition. 
Time profile of renal sympathetic nerve activity (RSA) response 
to bilateral carotid sinus nerve denervation (CSD) in SH (n=6) 
and Wistar (n=6) rats (a). Inset (b) shows the raw activity levels 
of RSA before and after CSD in one SH rat sitting quietly. The 
fall in RSA was ~55% relative to baseline in SH rats and 
significantly greater than in Wistar rats (c). Efficacy of CSD is 
shown in (d) where the sodium cyanide (i.v.) evoked RSA 
excitatory response was greatly attenuated. (e) A CSD SH rat 
showing that it is able to generate a robust RSA response to a 
stressful stimulus. Data shown as mean±sem *P<0.05, 
**P<0.01; between groups ANOVA, #P<0.05 repeated measures 
ANOVA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
Effects on the sympathetic baroreflex 
and vascular infiltration.  
(a) The renal sympathetic activity 
baroreflex function curve is rightward 
shifted over lower pressure ranges 
after carotid sinus nerve denervation 
(CSD) in SH rats (n=6) but no 
changes were observed in Wistar rats 
(n=6, Supplementary Fig S3). 
Percent total leukocytes (CD45+ 
cells) in the aorta of surgical sham 
(SS), RD and CSD animals (b).  
There was reduced vascular T cell 
infiltration following RD and CSD in 
the SH rats as the percentage of T 
lymphocytes (CD45+CD3+ cells) in 
the aorta of RD and CSD animals 
was less relative to SS (n= 6-
7/group); c). Representative flow 
cytometry contour plot showing T 
lymphocytes (CD45+CD3+) in aortic 
samples of each rat group (d). All 
data shown as mean±sem, ANOVA. 
*P<0.05 ANOVA. 
 
 
 
 
 
 
 
Figure 4 
Immediate effects of carotid 
sinus denervation. 
The time course of the fall in 
sympathetic nerve activity (raw 
and integrated) after carotid 
sinus nerve denervation (CSD) 
was compared for the internal 
cervical (iCSN) and lumbar 
(lSN) sympathetic post-
ganglionic nerves in situ. By 40 
min there was a significant 
decrease in sympathetic nerve 
activity in both outflows (a). 
Note the decrease in the 
amplitude of respiratory-
modulated discharge (P<0.05; 
b). The peak response was 
achieved at 60 min post CSD 
as activity levels at 75 or 90 min 
were not different to the level 
recorded at 40 min post CSD 
but were different to their own 
baseline (c). Data shown as 
mean±sem, *P<0.05, **P<0.01; 
***P<0.001 repeated measures 
ANOVA, n=>5. Abbreviations: 
PN, phrenic nerve; PP, 
perfusion pressure (aortic); Pre-
I, pre-inspiratory; TH, Traube-
Hering arterial pressure waves.  
 
 
 
 
 
 
 
Figure 5  
Unilateral carotid sinus 
denervation does not lower 
blood pressure in the rat. 
Unilateral carotid sinus nerve 
denervation (CSD) was 
ineffective at lowering SBP in 
SH rats whether the left or 
right CB was removed (n=8, 
a). Irrespective of whether the 
left or right CB was removed 
first, there was no difference in 
the fall in SBP observed on 
removal of the contralateral 
CB (b). Note that time 
staggered unilateral CB 
denervation does not affect 
the magnitude of the fall in 
SBP, which is the same as 
that seen when both left and 
right CB are denervated 
simultaneously (see Fig. 2 & 
3).Data shown as mean±sem, 
**P<0.01 within group 
ANOVA. 
 
 
 
 
 
 
 
 
Figure 6 
Carotid sinus and renal 
denervation interaction time 
course. 
Time profile of the SBP 
response to (a) renal nerve 
denervation (RD) followed by 
carotid sinus nerve denervation 
(CSD) (n=6) and (b) CSD 
followed by RD resection in SH 
rats (n=7). Note the time-
dependent increase in SBP in 
shams (n=6 and 7 
respectively). The 
completeness of the CSD is 
shown by the absence of a 
reflex pressor and bradycardic 
response following i.v. 
injections of sodium cyanide 
(NaCN; c). Data shown as 
mean±sem, repeated 
measures ANOVA: *P<0.05, 
**P<0.01; between group 
ANOVA ##P<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 
Carotid sinus and renal denervation interaction 
summary.  
Group data show the interaction between carotid 
sinus nerve denervation (CSD; n=6) and renal 
nerve denervation (RD; n=7) in SH rats. There 
was an additive effect of CSD and RD, 
irrespective of the order in which the intervention 
was made. The combined intervention produced 
a greater fall in SBP than each RD or CSD 
alone. Data shown as mean±sem, repeated 
measures ANOVA: * P<0.05, **P<0.01; between 
group ANOVA, #P<0.05. 
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